Mingfu Zhu
Nessuna posizione attualmente
Storia della carriera di Mingfu Zhu
Precedenti posizioni note di Mingfu Zhu
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
20n Bio
 20n Bio BiotechnologyHealth Technology 20n Bio is a venture-backed startup based in Malvern, PA. The company's focus is on generating protein drugs in silico with desired biophysical, functional, and pharmacological properties. The company was founded in 2021 by Mingfu Zhu and is dedicated to using artificial intelligence to design novel protein therapeutics to address unmet medical needs. | Fondatore | - | - |
Panorama Medicine, Inc.
 Panorama Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Panorama Medicine, Inc. operates a drug discovery platform that integrates genomics, big data, and computing to find drugs that can treat diseases caused by errors during RNA processing. The company was founded by Yi Xing, Mingfu Zhu, and Douglas Black in 2018 and is headquartered in Philadelphia, PA. | Direttore/Membro del Consiglio | 01/01/2018 | - |
| Amministratore Delegato | 01/01/2018 | - | |
| Fondatore | 01/01/2018 | - |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Settori
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Panorama Medicine, Inc.
Panorama Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Panorama Medicine, Inc. operates a drug discovery platform that integrates genomics, big data, and computing to find drugs that can treat diseases caused by errors during RNA processing. The company was founded by Yi Xing, Mingfu Zhu, and Douglas Black in 2018 and is headquartered in Philadelphia, PA. | Commercial Services |
20n Bio
20n Bio BiotechnologyHealth Technology 20n Bio is a venture-backed startup based in Malvern, PA. The company's focus is on generating protein drugs in silico with desired biophysical, functional, and pharmacological properties. The company was founded in 2021 by Mingfu Zhu and is dedicated to using artificial intelligence to design novel protein therapeutics to address unmet medical needs. | Health Technology |
- Borsa valori
- Insiders
- Mingfu Zhu
- Esperienza
